Retatrutide (a triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors) is a 39-amino-acid synthetic peptide currently in Phase 3 clinical research under the development designation LY3437943
The magnitude of change in cell function produced by exendin 9-39 was unaffected by acute FFA elevation
Customers in the 12-month cohort lost 28.2 pounds, or 12.2% of their initial body weight
Probiotic and Prebiotic Blend with 1 Billion CFU: Each serving of Xyro Research GLP1 Support Probiotic Berberine includes 1 Billion CFU from six probiotic strains plus 400 mg of prebiotic inulin fiber
no dairy, starch, sugar, wheat, gluten, yeast, soy, sesame, corn, egg, fish, shellfish, salt, tree nuts, or GMOs
See individual product page for important safety information